Dolasetron

DB00757

small molecule approved investigational

Deskripsi

Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.

Struktur Molekul 2D

Berat 324.38
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 8.1 hours
Volume Distribusi * 5.8 L/kg [adults]
Klirens (Clearance) * Apparent cl=9.4 mL/min/kg [Healthy volunteers with IV treatment dose up to 5 mg/kg]

Absorpsi

Orally-administered dolasetron is well absorbed

Metabolisme

Hepatic

Rute Eliminasi

Hydrodolasetron is eliminated by multiple routes, including renal excretion and, after metabolism, mainly glucuronidation, and hydroxylation.

Interaksi Makanan

1 Data
  • 1. Take with or without food. The absorption is unaffected by food.

Interaksi Obat

1164 Data
Ivabradine Ivabradine may increase the QTc-prolonging activities of Dolasetron.
Buprenorphine Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.
Hydrocodone Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Magnesium sulfate The therapeutic efficacy of Dolasetron can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Dolasetron may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.
Orphenadrine Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.
Pramipexole Dolasetron may increase the sedative activities of Pramipexole.
Ropinirole Dolasetron may increase the sedative activities of Ropinirole.
Rotigotine Dolasetron may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Dolasetron.
Sodium oxybate Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.
Thalidomide Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Dolasetron.
Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Dolasetron.
Phenindione The risk or severity of adverse effects can be increased when Dolasetron is combined with Phenindione.
Coumarin The risk or severity of adverse effects can be increased when Dolasetron is combined with Coumarin.
Tioclomarol The risk or severity of adverse effects can be increased when Dolasetron is combined with Tioclomarol.
Dicoumarol The risk or severity of adverse effects can be increased when Dolasetron is combined with Dicoumarol.
Warfarin The risk or severity of adverse effects can be increased when Dolasetron is combined with Warfarin.
Phenprocoumon The risk or severity of adverse effects can be increased when Dolasetron is combined with Phenprocoumon.
Acenocoumarol The risk or severity of adverse effects can be increased when Dolasetron is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of adverse effects can be increased when Dolasetron is combined with 4-hydroxycoumarin.
(R)-warfarin The risk or severity of adverse effects can be increased when Dolasetron is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Dolasetron is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of adverse effects can be increased when Dolasetron is combined with Fluindione.
Clorindione The risk or severity of adverse effects can be increased when Dolasetron is combined with Clorindione.
Diphenadione The risk or severity of adverse effects can be increased when Dolasetron is combined with Diphenadione.
(S)-Warfarin The risk or severity of adverse effects can be increased when Dolasetron is combined with (S)-Warfarin.
Mirabegron The serum concentration of Dolasetron can be increased when it is combined with Mirabegron.
Mirtazapine Dolasetron may increase the serotonergic activities of Mirtazapine.
Ethanol Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.
Sertraline The risk or severity of adverse effects can be increased when Dolasetron is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Dolasetron is combined with Sibutramine.
Zimelidine The risk or severity of adverse effects can be increased when Dolasetron is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Dolasetron is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Dolasetron is combined with Milnacipran.
Desvenlafaxine The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Dolasetron.
Seproxetine The risk or severity of adverse effects can be increased when Dolasetron is combined with Seproxetine.
Levomilnacipran The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Levomilnacipran.
Indalpine The risk or severity of adverse effects can be increased when Dolasetron is combined with Indalpine.
Alaproclate The risk or severity of adverse effects can be increased when Dolasetron is combined with Alaproclate.
Methylene blue Dolasetron may increase the serotonergic activities of Methylene blue.
Trospium The metabolism of Dolasetron can be decreased when combined with Trospium.
Tiotropium The metabolism of Tiotropium can be decreased when combined with Dolasetron.
Fesoterodine The metabolism of Fesoterodine can be decreased when combined with Dolasetron.
Umeclidinium The metabolism of Umeclidinium can be decreased when combined with Dolasetron.
Revefenacin The metabolism of Revefenacin can be decreased when combined with Dolasetron.
Doxepin The risk or severity of CNS depression can be increased when Dolasetron is combined with Doxepin.
Zopiclone The risk or severity of adverse effects can be increased when Dolasetron is combined with Zopiclone.
Citalopram The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Citalopram.
Anagrelide The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Anagrelide.
Disopyramide The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Disopyramide.
Clemastine The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Clemastine.
Ibutilide The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Ibutilide.
Grepafloxacin The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Grepafloxacin.
Toremifene The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Toremifene.
Imatinib The serum concentration of Dolasetron can be increased when it is combined with Imatinib.
Trovafloxacin The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Trovafloxacin.
Mifepristone The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Mifepristone.
Cocaine The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Cocaine.
Arsenic trioxide The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Arsenic trioxide.
Domperidone The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Domperidone.
Sparfloxacin The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Sparfloxacin.
Bepridil The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Bepridil.
Paliperidone The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Paliperidone.
Lithium cation The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Lithium cation.
Temafloxacin The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Temafloxacin.
Zuclopenthixol The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Zuclopenthixol.
Tetrabenazine The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Tetrabenazine.
Iloperidone The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Iloperidone.
Vandetanib The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Vandetanib.
Romidepsin The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Romidepsin.
Asenapine The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Asenapine.
Artemether The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Artemether.
Vemurafenib The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Vemurafenib.
Glasdegib The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Glasdegib.
Deutetrabenazine The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Deutetrabenazine.
Macimorelin The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Macimorelin.
Terodiline The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Terodiline.
Valproic acid The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Valproic acid.
Eliglustat The metabolism of Dolasetron can be decreased when combined with Eliglustat.
Dofetilide The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Dofetilide.
Cisapride The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Cisapride.
Quinidine The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Quinidine.
Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dolasetron.
Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dolasetron.
Erythromycin The serum concentration of Dolasetron can be increased when it is combined with Erythromycin.

Target Protein

5-hydroxytryptamine receptor 3A HTR3A

Referensi & Sumber

Synthesis reference: Janos Hajko, Tivadar Tamas, Adrienne Kovacsne-Mezei, Erika Molnarne, Csaba Peto, Csaba Szabo, "Production of dolasetron." U.S. Patent US20070203219, issued August 30, 2007.
Artikel (PubMed)
  • PMID: 9257083
    Balfour JA, Goa KL: Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs. 1997 Aug;54(2):273-98.
  • PMID: 9506240
    Gregory RE, Ettinger DS: 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89.
  • PMID: 15740177
    Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38.

Contoh Produk & Brand

Produk: 13 • International brands: 2
Produk
  • Anzemet
    Tablet, film coated • 100 mg/1 • Oral • US • Approved
  • Anzemet
    Tablet, film coated • 50 mg/1 • Oral • US • Approved
  • Anzemet
    Tablet, film coated • 100 mg/1 • Oral • US • Approved
  • Anzemet
    Injection • 12.5 mg/0.625mL • Intravenous • US • Approved
  • Anzemet
    Injection • 100 mg/5mL • Intravenous • US • Approved
  • Anzemet
    Injection • 500 mg/25mL • Intravenous • US • Approved
  • Anzemet
    Tablet, film coated • 100 mg/1 • Oral • US • Approved
  • Anzemet
    Tablet, film coated • 50 mg/1 • Oral • US • Approved
Menampilkan 8 dari 13 produk.
International Brands
  • Anemet — Sanofi-Aventis
  • Zamanon — Sanofi-Aventis

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul